Related Experiment Videos
The management of chronic hepatitis B infection
1Department of HIV Medicine, Chelsea & Westminster Hospital, London, UK.
Insights
Chronic hepatitis B infection, often sexually transmitted, requires targeted therapy for high-risk individuals. Interferon-alpha and lamivudine are licensed treatments, with combination nucleoside therapy emerging as a future choice.
Area of Science:
- Hepatology
- Virology
- Infectious Diseases
Background:
- Chronic hepatitis B infection is commonly diagnosed in genitourinary clinics, with sexual transmission being the primary route in the UK.
- Only 3-5% of adults with acute hepatitis B develop chronic infection, identifiable by persistent hepatitis B surface antigen (HBsAg).
- Hepatitis B e antigen (HBeAg) positive individuals with high hepatitis B virus (HBV) DNA levels face the highest risk of cirrhosis and hepatocellular carcinoma.
Purpose of the Study:
- To review current therapeutic options for chronic hepatitis B infection.
- To identify patient groups who would benefit most from therapy.
- To discuss future treatment strategies and patient management.
Main Methods:
- Review of licensed therapies for chronic hepatitis B.
- Analysis of seroconversion rates and treatment limitations for interferon-alpha and lamivudine.
- Discussion of emerging treatment modalities, including combination nucleoside therapy.
Main Results:
- Interferon-alpha achieves 30-40% seroconversion but is often limited by toxicity.
- Lamivudine is well-tolerated, with 15-20% seroconversion at one year, increasing with therapy duration.
- Development of resistance mutations limits long-term lamivudine monotherapy.
Conclusions:
- Therapy for chronic hepatitis B should target HBeAg positive patients with high HBV DNA.
- Interferon-alpha and lamivudine are current treatment options, each with specific efficacy and limitations.
- Combination nucleoside therapy is anticipated to be the future standard of care, alongside patient counseling on transmission, vaccination, and alcohol intake.
Abstract:
Chronic hepatitis B infection is frequently diagnosed within the genitourinary clinic setting with sexual transmission the commonest route of acquisition in the United Kingdom. Only 3--5% of adults who contract acute hepatitis B will progress to chronic infection, and these individuals can be identified by the presence of hepatitis B surface antigen (HBsAg) in the bloodstream 6 months after infection. Individuals at highest risk of long-term complications such as cirrhosis and hepatocellular carcinoma, carry HBeAg and have high levels of circulating hepatitis B virus (HBV) deoxyribonucleic acid (DNA). Therapy should be targeted towards this group of patients. Two forms of therapy are now licensed for use in chronic hepatitis B infection: interferon-alpha and lamivudine. Seroconversion occurs in 30--40% of patients treated with interferon and treatment is often limited by toxicity. Lamivudine is well tolerated with seroconversion rates of 15--20% at one year, rising with increasing duration of therapy. Long-term monotherapy is limited however by the development of resistance mutations and combination nucleoside therapy is likely to become the treatment of choice in the future. Patients with chronic hepatitis B should be counselled regarding transmission, partner vaccination and alcohol intake and co-infection with other hepatitis viruses should be excluded.